Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Eastern Bank increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 145.8% in the 3rd quarter, according ...

Xcel Wealth Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 8.3% during the 3rd quarter, Holdings Channel reports. The fund owned 509 shares of the company’s ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...